PT Medikaloka Hermina Tbk (ISX:HEAL) EBIT: Rp949,393 Mil (TTM As of Mar. 2026)


ISX:HEAL PT Medikaloka Hermina Tbk ISX:HEAL
72 GF Score
Price Rp840.00
GF Value Rp1,577.62
Valuation Significantly Undervalued
! 5 Warning Signs
View Full Analysis

What is PT Medikaloka Hermina Tbk EBIT?

PT Medikaloka Hermina Tbk ISX:HEAL -0.59% 72 EBIT is Rp949,393 Mil as of Mar. 2026. GuruFocus rates ISX:HEAL with a GF Score™ of 72/100 and a GF Value™ of Rp1,577.62 (Significantly Undervalued). The stock has 5 warning signs investors should review.

PT Medikaloka Hermina Tbk's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was Rp226,828 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was Rp949,393 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. PT Medikaloka Hermina Tbk's annualized ROC % for the quarter that ended in Mar. 2026 was 6.46%. PT Medikaloka Hermina Tbk's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 9.70%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. PT Medikaloka Hermina Tbk's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 5.53%.

PT Medikaloka Hermina Tbk  (ISX:HEAL) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

PT Medikaloka Hermina Tbk's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=863228 * ( 1 - 22.6% )/( (10321740 + 10349660)/ 2 )
=668138.472/10335700
=6.46 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=11887060 - 1137636 - ( 727793 - max(0, 1939201 - 2366885+727793))
=10321740

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=12079165 - 1076713 - ( 844634 - max(0, 1791953 - 2444745+844634))
=10349660

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

PT Medikaloka Hermina Tbk's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=907312/( ( (9131415 + max(179210, 0)) + (9130888 + max(271053, 0)) )/ 2 )
=907312/( ( 9310625 + 9401941 )/ 2 )
=907312/9356283
=9.70 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1313752 + 168953 + 54805) - (1137636 + 0 + 220664)
=179210

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1275092 + 151518 + 48516) - (1076713 + 0 + 127360)
=271053

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

PT Medikaloka Hermina Tbk's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=949393/17155381.984
=5.53 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PT Medikaloka Hermina Tbk EBIT Related Terms

PT Medikaloka Hermina Tbk EBIT Historical Data

* Premium members only.

The historical data trend for PT Medikaloka Hermina Tbk's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PT Medikaloka Hermina Tbk EBIT Chart

PT Medikaloka Hermina Tbk Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,789,689.00 619,921.00 849,953.00 1,086,248.00 993,322.00

PT Medikaloka Hermina Tbk Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 270,757.00 219,672.00 280,873.00 222,020.00 226,828.00

ISX:HEAL vs HCA, THC, DVA: EBIT Comparison

For the Medical Care Facilities subindustry, PT Medikaloka Hermina Tbk's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PT Medikaloka Hermina Tbk EV-to-EBIT vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, PT Medikaloka Hermina Tbk's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where PT Medikaloka Hermina Tbk's EV-to-EBIT falls into.


ISX:HEAL
72GF Score
PT Medikaloka Hermina Tbk ISX:HEAL
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PT Medikaloka Hermina Tbk EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was Rp949,393 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of Rp949,393 Mil mean?
PT Medikaloka Hermina Tbk (ISX:HEAL) has a EBIT of Rp949,393 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on PT Medikaloka Hermina Tbk.
Is PT Medikaloka Hermina Tbk's EBIT too high?
PT Medikaloka Hermina Tbk's current EBIT is Rp949,393 Mil. Overall, PT Medikaloka Hermina Tbk has a GF Score™ of 72/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PT Medikaloka Hermina Tbk's EBIT compare to HCA and THC?
PT Medikaloka Hermina Tbk's EBIT of Rp949,393 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Healthcare Providers & Services company?
A good EBIT depends on the Healthcare Providers & Services industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on PT Medikaloka Hermina Tbk. PT Medikaloka Hermina Tbk's current EBIT is Rp949,393 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Medikaloka Hermina Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Medikaloka Hermina Tbk (ISX:HEAL) is currently considered Significantly Undervalued. The stock's GF Value™ is Rp1,577.62, compared to a current price of Rp840.00 — trading 46.8% below its estimated fair value. The current EBIT is Rp949,393 Mil. PT Medikaloka Hermina Tbk's overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For PT Medikaloka Hermina Tbk (ISX:HEAL), the current EBIT is Rp949,393 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PT Medikaloka Hermina Tbk (ISX:HEAL) Overvalued in 2026?

Based on GuruFocus' analysis, PT Medikaloka Hermina Tbk stock appears to be undervalued. The current stock price of Rp840.00 is trading 46.8% below its estimated GF Value™ of Rp1,577.62. GuruFocus considers PT Medikaloka Hermina Tbk to be Significantly Undervalued.

Key valuation signals for ISX:HEAL:

  • EBIT: Rp949,393 Mil
  • GF Value™: Rp1,577.62 vs. price of Rp840.00 (46.8% below fair value)
  • GF Score™: 72/100 with 5 warning signs

No single metric tells the full story. See the ISX:HEAL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PT Medikaloka Hermina Tbk Business Description

Address Jalan Selangit B-10 Kavling No. 4, Hermina Tower, Kemayoran, Jakarta, IDN, 10610
PT Medikaloka Hermina Tbk is a private hospital group. It provides a range of medical services, including maternal and child health services, complex operating procedures, laboratory services, radiology facilities, and fertility treatments as well as general health services, pharmacies, diagnostic and emergency services. The company's geographical segment includes Kalimantan dan Sulawesi, Jawa, and Sumatera. It derives maximum revenue from the Jawa segment.
72GF Score

Get the complete analysis for ISX:HEAL

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

Rp840.00
Price
Rp1,577.62
GF Value